Clinical Trials on CML

Total 1097 results

University of Jena
Novartis Pharmaceuticals; Ludwig-Maximilians - University of Munich

Active, not recruiting

Frontline Asciminib Combination in Chronic Phase CML (CMLXI)

Chronic Myeloid Leukemia

Germany
Hybrigenics Corporation

Unknown

Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study (ICT10)

CML, Chronic Phase

France
MEI Pharma, Inc.
Kyowa Kirin, Inc.

Withdrawn

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL (CORAL)

CLL

United States
University Hospital Inselspital, Berne

Withdrawn

Epacadostat, Cladribine and Cytarabine (ECC) in AML (ECC)

AML | Relapse

Switzerland
Chinese PLA General Hospital
Navy General Hospital, Beijing

Unknown

Chidamide Plus DCAG for Relapsed/Refractory AML

AML | Relapse

China
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Completed

Phase I Study in RAD 001 Patients With Relapse AML

AML

France
Memorial Sloan Kettering Cancer Center

Terminated

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Acute Lymphoid Leukemia (ALL)

United States
Tarapeutics Science Inc.

Recruiting

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CMV-TCR-T Cells for CM Virus Infection After HSCT

CMV Infection or Reactivation After Allogenic HSCT

China
PETHEMA Foundation

Terminated

LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)

AML

Spain
Tarapeutics Science Inc.

Recruiting

A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
Eidos Therapeutics, a BridgeBio company

Completed

Study of AG10 in Amyloid Cardiomyopathy

Familial ATTR-CM (ATTRm-CM, or FAC) | Wild-type ATTR-CM (ATTRwt-CM)

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With CLL/ SLL

CLL/SLL

China
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

AML | MDS

France
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

CLL/SLL

Netherlands, Belgium, Denmark
University of Konstanz
Ludwig-Maximilians - University of Munich; Jimma University

Completed

The Impact of Lifestyle on Mental Health Among Young Men in the Gilgel Gibe Field Research Center, Ethiopia: Pilot Study

Common Mental Disorders (CMD) | Psychotic Symptoms
Nordic MDS Group

Completed

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

AML | MDS

Denmark, Norway, Sweden
Peking University People's Hospital

Recruiting

CMV Infection and Immune Intervention After Transplantation

Transplantation Infection | CMV Viremia

China
Gamida Cell ltd

Active, not recruiting

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Lymphoma | Acute Leukemia | Hematological Malignancies | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML)

Spain, United States, United Kingdom, Israel, Singapore, Brazil, Italy, France, Netherlands, Portugal
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML)

United States
Michael Morse, MD

Terminated

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation (WT-1)

Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | B Cell Malignancies | Chronic Myelogenous Leukemia (CML)

United States
Cao Weijie

Recruiting

Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT

Letemovir for the Prevention of CMV Infection After Allo-HSCT

China
Memorial Sloan Kettering Cancer Center

Recruiting

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

CMV Infection | Persistent CMV Viremia

United States
University of Wisconsin, Madison
University of Wisconsin Carbone Cancer Center (UWCCC)

Recruiting

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

Cytomegalovirus Infections | Opportunistic Infections | CMV Infection | CMV Viremia

United States
xuna

Recruiting

A Study for PRO of CML in Real Word (Case-Only)

CML (Chronic Myelogenous Leukemia)

China
Novartis Pharmaceuticals

No longer available

Nilotinib, for Patients With CML-CP or CML-AP

Chronic Myelogenous Leukemia (CML)
Bristol-Myers Squibb

Completed

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Leukemia, Myeloid, Chronic-Phase (CML-CP)
Novartis Pharmaceuticals

Completed

Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Chronic Myeloid Leukemia (CML)

Korea, Republic of
BioNova Pharmaceuticals (Shanghai) LTD.

Recruiting

A Study of BN104 in the Treatment of Acute Leukemia

AML, Adult | ALL, Adult

China
MacroGenics

Terminated

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) (VOYAGE)

AML

United States, United Kingdom, Germany, Israel, Spain, France, Italy, Netherlands
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

SARS-CoV-2 Donor-Recipient Immunity Transfer

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | COVID-19 Infection | Accelerated Phase... and other conditions

United States
Zhongnan Hospital

Recruiting

An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

UCB (Cord Blood) Microtransplantation in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

China
French Innovative Leukemia Organisation
Bristol-Myers Squibb

Completed

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy (RESIST)

Small Lymphocytic Leukemia | CLL, Relapsed | CLL, Refractory | Bruton Tyrosine Kinase Inhibitor

France
Amgen

Terminated

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

Myelodysplastic Syndrome | Relapsed/Refractory AML | Minimal Residual Disease Positive AML

United States, Canada, Germany, Netherlands
AstraZeneca

Active, not recruiting

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

Part1: Advanced B-cell Malignancies | Part2: r/rCLL and r/rMCL | Part3: Untreated CLL

Japan
BioNova Pharmaceuticals (Shanghai) LTD.

Withdrawn

A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

NHL | CLL/SLL

China
Mahidol University

Completed

Stool and Serum CMV-PCR in Diagnosing CMV Colitis

CMV Colitis

Thailand
University of Wisconsin, Madison

Terminated

FLT-PET Imaging for MDS

AML | MDS

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

AML | MDS

China
Assiut University

Not yet recruiting

Prognostic Role of Platelet _lymphocyte and Neutrophil _monocyte in CLL

CLL Progression
Aptevo Research and Development LLC

Recruiting

Study of APVO436 in Patients With AML or MDS

AML | MDS

United States
EDDC (Experimental Drug Development Centre), A*STAR...
Chiltern International Inc.

Withdrawn

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) | Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)

United States, Singapore
Hutchmed

Withdrawn

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma | NHL | DLBCL | Richter Syndrome | CLL/SLL | MCL | MZL

United States, Spain, Australia, Israel, Italy, Poland, France
Celgene

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)

United States
Novartis Pharmaceuticals

No longer available

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy (AMLFLT3)

Acute Myeloid Leukemia (AML) With | FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)

United States
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML)

China
Fate Therapeutics

Completed

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

Chronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Non-Hodgkin's Lymphoma (NHL) | Hodgkin's Disease | Acute Myelogenous Leukemia (AML)

United States
Institut de Recherches Internationales Servier

Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic Malignancies

United States, France

Clinical Trials on CML

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations